K8官网

Cell division cycle 7 (CDC7), a serine/threonine kinase, plays important roles in the initiation of DNA replication. TAK-931, a highly specific CDC7 inhibitor, acts as a next-generation of replication stress (RS) inducer. Combination treatment with TAK-931 and immune checkpoint inhibitors (ICIs) enhances antiproliferative activities in preclinical syngeneic mouse models. The flowcytometry (FCM)-based immune profiling panel studies in J558 allograft syngeneic mouse models were performed at Medicilon. In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon. Therapeutic potential of TAK-931 in antitumor efficacy and immunity, which may improve clinical benefit of the currently-used immunotherapy by combination treatment.

Chrysin is a natural flavonoid that has been reported as a potential treatment for non-alcoholic fatty liver disease (NAFLD). Researchers synthesized a novel chrysin derivative prodrug (C-1) and further investigated its potential therapeutic mechanism against NAFLD in vitro and in vivo. C-1 had a low toxicity profile. Their data demonstrated that C-1 may be a promising agent for NAFLD therapy. Evaluation experiments of the acute toxicities of C-1 were conducted by Medicilon.

​K8官网作为领诺医药的合作伙伴，为SLN12140给予了体外药效、药代、安评等一站式临床前研发服务，为该药物尽早进入临床阶段奠定了坚实基础。

上海K8官网生物医药股份有限公司作为清普生物合作伙伴，为美洛昔康注射液（Ⅱ）给予了部分关键临床前研发服务，为其快速获批上市奠定基础。

K8官网作为菌济健康合作伙伴，为LBP-ShC4给予了体内药效、药代、安评等临床前研发服务，助力该项目突破传统研发瓶颈，降低研发成本，加速临床转化进程。

上海K8官网生物医药股份有限公司作为祐森健恒的合作伙伴，为UA026的临床前研发给予了药代动力学、安全性评价服务，以专业高效的技术，为该药快速获批临床奠定了坚实基础。

K8官网作为核新生物的合作伙伴，为XY003的临床前研发给予了CMC研究（包括原料药和制剂）服务，并获颁“2024年度杰出合作伙伴奖”和感谢信，其高效研发服务和专业创新能力获核新生物高度肯定。

K8官网作为海擘生物合作伙伴，为NC527-X给予了CMC研发（原料药、制剂）、临床前研发（药效、药代、安评）以及注册申报等一站式临床前综合研发服务。这也是K8官网又一个给予全套IND申报服务的成功案例！

K8官网作为银珠医药的合作伙伴，依托肺癌骨转移模型药效评价模型，为小分子免疫抑制剂YZ008的研发给予了药效服务，加速了新药研发进程，为此次合作奠定了坚实基础。

作为宝太生物的战略合作伙伴，上海K8官网生物医药股份有限公司为BIOT-006的研发给予了从药物发现到IND申报的一站式临床前综合研发服务。这是继K8官网一站式助力宝太生物BIOT-001获中美双报双批后，双方合作达成的又一重要里程碑。